Precision Editing of Myosin Phosphatase as a Novel Approach for Vasodilator Sensitization and Lowering of Blood Pressure in Hypertension

肌球蛋白磷酸酶的精确编辑作为高血压患者血管扩张剂增敏和降血压的新方法

基本信息

  • 批准号:
    10265343
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-01-01 至 2022-12-31
  • 项目状态:
    已结题

项目摘要

High blood pressure (BP) is endemic, and despite vasodilator and diuretic therapy, still accounts for much cardiovascular morbidity (heart failure, stroke) and mortality in the veteran population. Our studies focus on Myosin Phosphatase (MP), which by de-phosphorylating myosin causes smooth muscle relaxation. MP is the target of most constrictor and dilator signaling pathways that regulate vascular tone and thereby control BP. Over years of study we have proposed a model in which alternative splicing of Exon 24 (E24) of the MP regulatory subunit Mypt1 tunes vascular smooth muscle sensitivity to nitric oxide (NO)/ cGMP-mediated vasorelaxation. Inclusion of the 31 nt E24 shifts the reading frame, thereby coding for an isoform of Mypt1 lacking the C- terminal leucine zipper (LZ) motif required for cGMP-dependent kinase (cGK1α) activation of MP and vasorelaxation. Others have shown that the inhibitory subunit of MP, CPI17, is a key target of signals that inhibit MP and thereby cause vasoconstriction. The increased vascular resistance of hypertension is in part due to reduced bio-availability of NO reducing vasodilator signaling, and neurohumoral activation increasing vasoconstrictor signaling. Here we propose to test in an animal model of hypertension novel strategies involving precision editing of the MP regulatory and inhibitory subunits aimed at shifting the balance of constrictor and dilator signaling in order to lower vascular resistance and BP. Aims 1 and 2 will test vasodilator sensitization via precision editing of MP regulatory subunit Mypt1 Exon 24 (E24). Aim 3 will test vasoconstrictor de-sensitization via precision editing of the MP inhibitory subunit CPI17. Aim 1 will develop Adeno-Associated Viral delivery of Crispr/Cas9 editing (deletion) of E24 to test if this approach can reverse vasodysfunction in the AngII mouse model of hypertension. Aim 2 will use our recently developed and validated Cre-Lox mouse model that achieves robust editing of the same target, and compares approaches of primordial prevention vs treatment after hypertension is established. Aim 3 will develop Adeno-Associated Viral delivery of Crispr/Cas9 editing of CPI17 to test if this approach can suppress the increased vasoconstrictor signaling in the AngII mouse model of hypertension. Molecular assays will determine mechanisms by which dilator and constrictor signals are integrated by MP in the control of BP in normal and hypertensive animals, and how this balance is altered by precision editing of the MP subunits. These experiments, with high potential for translation to Veterans, will test a novel strategy of vasodilator sensitization/vasoconstrictor desensitization for permanent lowering of BP, and will define mechanisms by which signals converge on MP to cause vasodysfunction in models of hypertension.
高血压(BP)是地方性的,尽管有血管扩张剂和利尿剂治疗, 退伍军人人群的心血管发病率(心力衰竭、中风)和死亡率。我们的研究集中在 肌球蛋白磷酸酶(MP),通过去磷酸化肌球蛋白引起平滑肌松弛。MP是 调节血管张力从而控制血压的大多数收缩和扩张信号通路的靶点。超过 经过多年的研究,我们提出了一个模型,其中MP的外显子24(E24)的选择性剪接调节 Mypt 1亚基调节血管平滑肌对一氧化氮(NO)/cGMP介导的血管舒张的敏感性。 包含31 nt E24使阅读框移位,从而编码缺少C-末端的Mypt 1同种型。 MP的cGMP依赖性激酶(cGK 1 α)激活所需的末端亮氨酸拉链(LZ)基序, 血管舒张其他人已经表明MP的抑制性亚基CPI 17是抑制信号的关键靶点, MP,从而引起血管收缩。高血压的血管阻力增加部分是由于 NO的生物利用度降低,血管舒张信号减少,神经体液激活增加 血管收缩信号 在这里,我们提出在高血压动物模型中测试涉及精确编辑的新策略。 MP调节和抑制亚单位旨在改变收缩和扩张信号的平衡, 以降低血管阻力和血压。目标1和2将通过精确编辑测试血管扩张剂致敏性 MP调节亚基Mypt 1外显子24(E24)的表达。目标3将通过精确度测试血管收缩剂去敏作用 MP抑制亚基CPI 17的编辑。 目标1将开发E24的Crispr/Cas9编辑(缺失)的腺相关病毒递送,以测试这是否 方法可以逆转高血压AngII小鼠模型中的血管功能障碍。 Aim 2将使用我们最近开发和验证的Cre-Lox小鼠模型,该模型实现了对 相同的目标,并比较了高血压病确立后的原始预防与治疗方法。 Aim 3将开发CPI 17的Crispr/Cas9编辑的腺相关病毒递送,以测试这种方法是否可以 抑制高血压AngII小鼠模型中增加的血管收缩信号传导。 分子分析将确定扩张器和收缩器信号通过以下方式整合的机制: MP在正常和高血压动物中控制BP,以及这种平衡如何通过精确编辑改变 MP亚单位的。这些实验,具有很高的潜力翻译为退伍军人,将测试一部小说 血管扩张剂增敏/血管收缩剂脱敏策略,永久性降低血压,以及 将定义信号会聚在MP上导致血管功能障碍的机制, 高血压

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Steven A. Fisher其他文献

The application of SOM as a decision support tool to identify AACSB peer schools
  • DOI:
    10.1016/j.dss.2008.12.010
  • 发表时间:
    2009-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Melody Y. Kiang;Dorothy M. Fisher;Jeng-Chung Victor Chen;Steven A. Fisher;Robert T. Chi
  • 通讯作者:
    Robert T. Chi

Steven A. Fisher的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Steven A. Fisher', 18)}}的其他基金

Precision Editing of Myosin Phosphatase for Vasodilator Sensitization in Hypertension
肌球蛋白磷酸酶的精确编辑对高血压血管舒张剂的敏感性
  • 批准号:
    10338049
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Precision Editing of Myosin Phosphatase for Vasodilator Sensitization in Hypertension
肌球蛋白磷酸酶的精确编辑对高血压血管舒张剂的敏感性
  • 批准号:
    10090622
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Precision Editing of Myosin Phosphatase for Vasodilator Sensitization in Hypertension
肌球蛋白磷酸酶的精确编辑对高血压血管舒张剂的敏感性
  • 批准号:
    9894837
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Precision Editing of Myosin Phosphatase as a Novel Approach for Vasodilator Sensitization and Lowering of Blood Pressure in Hypertension
肌球蛋白磷酸酶的精确编辑作为高血压患者血管扩张剂增敏和降血压的新方法
  • 批准号:
    10436920
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
NIH - NHLBI - Re-Entry Supplement to Existing R01 Variant surface antigens in cerebral malaria pathogenesis
NIH - NHLBI - 脑型疟疾发病机制中现有 R01 变异表面抗原的重新进入补充
  • 批准号:
    9443388
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
Variant surface antigens in cerebral malaria pathogenesis
脑型疟疾发病机制中的变异表面抗原
  • 批准号:
    9144853
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
Variant surface antigens in cerebral malaria pathogenesis
脑型疟疾发病机制中的变异表面抗原
  • 批准号:
    9019218
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
RETINAL CELL REMODELING UTILIZING ADVANCED IMAGING TECHNOLOGY
利用先进成像技术重塑视网膜细胞
  • 批准号:
    8361929
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
RETINAL CELL REMODELING UTILIZING ADVANCED IMAGING TECHNOLOGY
利用先进成像技术重塑视网膜细胞
  • 批准号:
    8169644
  • 财政年份:
    2010
  • 资助金额:
    --
  • 项目类别:
NEURONAL REMODELING AFTER RETINAL DETACHMENT AND DURING RECOVERY
视网膜脱离后和恢复期间的神经元重塑
  • 批准号:
    7358149
  • 财政年份:
    2006
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Alternative splicing of Grin1 controls NMDA receptor function in physiological and disease processes
Grin1 的选择性剪接控制生理和疾病过程中的 NMDA 受体功能
  • 批准号:
    488788
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
Using proteogenomics to assess the functional impact of alternative splicing events in glioblastoma
使用蛋白质基因组学评估选择性剪接事件对胶质母细胞瘤的功能影响
  • 批准号:
    10577186
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Long Noncoding RNA H19 Mediating Alternative Splicing in ALD Pathogenesis
长非编码 RNA H19 介导 ALD 发病机制中的选择性剪接
  • 批准号:
    10717440
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing
RBFOX2 失调通过选择性剪接促进胰腺癌进展
  • 批准号:
    10638347
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Alternative splicing regulation of CLTC in the heart
心脏中 CLTC 的选择性剪接调节
  • 批准号:
    10749474
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Nitric oxide as a novel regulator of alternative splicing
一氧化氮作为选择性剪接的新型调节剂
  • 批准号:
    10673458
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Alternative splicing as an evolutionary driver of phenotypic plasticity
选择性剪接作为表型可塑性的进化驱动力
  • 批准号:
    2884151
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Studentship
Rescuing SYNGAP1 haploinsufficiency by redirecting alternative splicing
通过重定向选择性剪接挽救 SYNGAP1 单倍体不足
  • 批准号:
    10660668
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
CAREER: Mechanotransduction, transcription, and alternative splicing in cell biology
职业:细胞生物学中的机械转导、转录和选择性剪接
  • 批准号:
    2239056
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Continuing Grant
Investigating the role of alternative splicing in the islets of Langerhans in developing diabetes.
研究朗格汉斯岛中选择性剪接在糖尿病发生中的作用。
  • 批准号:
    468851650
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Research Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了